Wang, Z.; Mi, T.; Bradley, H.L.; Metts, J.; Sabnis, H.; Zhu, W.; Arbiser, J.; Bunting, K.D.
Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia. Antioxidants 2021, 10, 956.
https://doi.org/10.3390/antiox10060956
AMA Style
Wang Z, Mi T, Bradley HL, Metts J, Sabnis H, Zhu W, Arbiser J, Bunting KD.
Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia. Antioxidants. 2021; 10(6):956.
https://doi.org/10.3390/antiox10060956
Chicago/Turabian Style
Wang, Zhengqi, Tian Mi, Heath L. Bradley, Jonathan Metts, Himalee Sabnis, Wandi Zhu, Jack Arbiser, and Kevin D. Bunting.
2021. "Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia" Antioxidants 10, no. 6: 956.
https://doi.org/10.3390/antiox10060956
APA Style
Wang, Z., Mi, T., Bradley, H. L., Metts, J., Sabnis, H., Zhu, W., Arbiser, J., & Bunting, K. D.
(2021). Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia. Antioxidants, 10(6), 956.
https://doi.org/10.3390/antiox10060956